DTC spend down 3% in '07

Share this article:
Drug industry spend on consumer advertising dropped 3% in 2007 to $5.15 billion, from $5.31 billion in 2006, but spending on product advertising, particularly TV and print, continued to climb. 

Pharmas cut back sharply on corporate advertising—from $577 million in 2006 to $247 million in 2007, according to TNS Media Intelligence. But product advertising was up 3% to $4.9 billion, from $4.73 billion in 2006. 

For product advertising, newspapers took a hit as spending was halved, to $75 million from $152 million. Radio spend fell 45%, from $55 million to $30 million. Perhaps most remarkably, Internet spending slid 5%, from $163 million to $155 million, though that figure reflects display advertising—not spend on search engine optimization or websites. 

Spending on TV product ads rose 7% to $2.87 billion from $2.66 billion in 2006, while spending on product ads in magazines climbed 4% to $1.76 billion from $1.68 billion in 2006.

The numbers suggest that pharmas are still leaning heavily on mass-market “shotgun” channels to drive awareness of the products, but that marketers, under pressure to cut costs, are trimming where they can. Overall spend has seen steady increases for a decade, but some spending may be shifting toward less-measurable means of reaching consumers, such as websites and online CRM. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what ...

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...